Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society - 1 May 2014

Meyer Larissa A, Slomovitz Brian M, Djordjevic Bojana, Westin Shannon N, Iglesias David A, Munsell Mark F, Jiang Yunyun, Schmandt Rosemarie, Broaddus Russell R, Coleman Robert L, Galbincea John M, Lu Karen H

Abstract excerpt

OBJECTIVE: PI3K/mammalian target of rapamycin (mTOR) pathway aberrations occur in 40% to 80% of endometrial cancer. Prior studies suggest KRAS mutations are associated with resistance to mTOR inhibitors in solid tumors. The objective of this study was to determine if biomarker expression in the PI3K/mTOR pathway or KRAS mutations would predict response to therapy with everolimus, an mTOR inhibitor. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Endometrial Neoplasms
Share to Everolimus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoenzyme Techniques

Share to Neoplasm Grading

Share to PTEN Phosphohydrolase

Share to Ribosomal Protein S6 Kinases, 70-kDa

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 24651628
DOI: 10.1097/IGC.0000000000000118
PMCID: PMC4039301

Genes

KRAS
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.PMID 24651628Read ↗

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.Semantic proximity Read ↗

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.Semantic proximity Read ↗

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.Semantic proximity Read ↗

PI3K pathway dependencies in endometrioid endometrial cancer cell lines.Semantic proximity Read ↗

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.Semantic proximity Read ↗

Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.Semantic proximity Read ↗

Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.Semantic proximity Read ↗

Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.Semantic proximity Read ↗

Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinomaSemantic proximity Read ↗

MicroRNA-199a-3p Regulates Endometrial Cancer Cell Proliferation by Targeting Mammalian Target of Rapamycin (mTOR)Semantic proximity Read ↗

Coexistent <i>PTEN</i> and <i>PIK3CA</i> alterations hyperactivate mTORC1 signaling in endometrial cancers and cause their selective sensitivity to mTORC1 inhibitionSemantic proximity Read ↗

Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.